BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Exp Med. Jun 20, 2026; 16(2): 119440
Published online Jun 20, 2026. doi: 10.5493/wjem.v16.i2.119440
Table 1 Baseline characteristics of the study population, mean ± SD/n (%)
Variable
TII/TID, n = 52
TII + TID, n = 48
Total, n = 100
P value
Age (year)26.08 ± 14.8929.79 ± 10.6927.86 ± 13.120.158
Systolic BP (mmHg)125.10 ± 24.87133.74 ± 30.75129.24 ± 28.030.132
Diastolic BP (mmHg)74.30 ± 15.9280.28 ± 17.6577.17 ± 16.950.084
Urine protein (g)3.35 ± 4.522.97 ± 2.713.17 ± 3.750.615
Serum creatinine (µmol/L)121.27 ± 162.65126.75 ± 120.38123.92 ± 143.020.852
eGFR (mL/minute/1.73 m2)98.21 ± 52.7177.67 ± 37.3788.35 ± 46.910.028
Hemoglobin (g/dL)10.51 ± 2.0513.87 ± 16.9012.12 ± 11.850.161
WBC count (× 109/L)7.17 ± 3.897.04 ± 4.027.10 ± 3.930.888
Platelet count (× 109/L)230.67 ± 135.81236.26 ± 150.98233.53 ± 142.940.859
PTH (pmol/L)8.09 ± 14.359.33 ± 10.098.72 ± 12.300.674
C3 (g/L)0.70 ± 0.460.67 ± 0.300.69 ± 0.390.648
C4 (g/L)0.17 ± 0.150.14 ± 0.090.16 ± 0.130.248
Total protein in serum (g/L)52.37 ± 17.0451.50 ± 16.0251.93 ± 16.420.825
Albumin in serum (g/L)28.50 ± 7.5927.66 ± 7.0628.09 ± 7.320.571
Total cholesterol (mmol/L)4.75 ± 4.324.70 ± 2.364.72 ± 3.440.951
LDL-C (mmol/L)1.78 ± 1.823.01 ± 1.882.40 ± 1.940.006
HDL-C (mmol/L)0.91 ± 0.860.94 ± 0.560.93 ± 0.720.843
TG (mmol/L)1.32 ± 0.961.57 ± 0.861.45 ± 0.910.253
HA1C at diagnosis (%)3.74 ± 3.004.70 ± 1.614.19 ± 2.480.069
Sodium (mmol/L)137.80 ± 4.06135.53 ± 5.72136.65 ± 5.070.058
Potassium (mmol/L)4.23 ± 0.604.42 ± 0.704.32 ± 0.650.226
Calcium (mmol/L)2.05 ± 0.492.09 ± 0.242.07 ± 0.390.626
Phosphorus (mmol/L)1.30 ± 0.651.22 ± 0.381.26 ± 0.540.517
Uric acid (µmol/L)313.23 ± 193.36383.15 ± 178.02349.14 ± 187.680.11
CRP (mg/L)10.98 ± 17.3512.85 ± 28.6611.88 ± 23.400.703
ANA1.20 ± 0.401.07 ± 0.261.14 ± 0.350.077
ANA titer or dilution621.71 ± 584.77687.78 ± 492.12655.21 ± 536.930.608
Anti ds-DNA1.24 ± 0.651.45 ± 0.541.34 ± 0.610.085
Anti ds-DNA titer215.29 ± 512.00125.32 ± 355.03172.14 ± 443.780.319
Anti SM antibody16.59 ± 81.411.92 ± 7.119.15 ± 57.430.285
Anti RNP antibody positivity0.69 ± 4.060.00 ± 0.000.34 ± 2.850.314
Modified NIH Activity score3.13 ± 3.186.17 ± 3.904.59 ± 3.840
Chronicity score1.85 ± 2.444.21 ± 1.742.98 ± 2.430
Gender
    Female43 (82.7)41 (85.4)84 (84.0)0.71
    Male9 (17.3)7 (14.6)16 (16.0)
Class
    I/II7 (13.5)1 (2.1)8 (8.0)0.024a
    III8 (15.4)17 (35.4)25 (25.0)
    III and V5 (9.6)8 (16.7)13 (13.0)
    IV11 (21.2)7 (14.6)18 (18.0)
    IV and V8 (15.4)10 (20.8)18 (18.0)
    V/VI13 (25.0)5 (10.4)18 (18.0)
Hypertension
    Yes33 (64.7)38 (79.2)71 (71.7)0.11
    No18 (35.3)10 (20.8)28 (28.3)
DM
    Yes6 (12.0)9 (19.1)15 (15.5)0.33
    No44 (88.0)38 (80.9)82 (84.5)
Induction drug: CYC15 (28.8)9 (18.8)24 (24.0)0.292
MMF36 (69.2)39 (81.3)75 (75.0)
MMF + CYC1 (1.9)0 (0.0)1 (1.0)
Maintenance (yes)5 (9.6)2 (4.2)7 (7.0)0.502
MMF (maintenance)38 (73.1)42 (87.5)80 (80.0)
Azathioprine (AZA)3 (5.8)3 (6.3)6 (6.0)
MMF + CNI3 (5.8)1 (2.1)4 (4.0)
MMF or AZA1 (1.9)0 (0.0)1 (1.0)
MMF+ AZA + CNI1 (1.9)0 (0.0)1 (1.0)
Podocyte effacement ≥ 5027 (52.9)22 (46.8)49 (50.0)0.083
Podocyte effacement < 5014 (27.5)7 (14.9)21 (21.4)
No comment or not done10 (19.6)18 (38.3)28 (28.6)
EM mesangium deposits3 (6.0)14 (30.4)17 (17.7)0.007a
EM
    Yes26 (52.0)16 (34.8)42 (43.8)
    No21 (42.0)16 (34.8)37 (38.5)
Full house30 (63.8)21 (52.5)51 (58.6)0.285
Partial17 (36.2)19 (47.5)36 (41.4)
Statin
    Yes17 (34.0)17 (36.2)34 (35.1)0.823
    No33 (66.0)30 (63.8)63 (64.9)
ACEI
    Yes24 (55.8)27 (64.3)51 (60.0)0.425
    No19 (44.2)15 (35.7)34 (40.0)
ARB
    Yes22 (47.8)23 (56.1)45 (51.7)0.441
    No24 (52.2)18 (43.9)42 (48.3)
SGLT-2
    Yes4 (7.8)4 (8.5)8 (8.2)0.904
    No47 (92.2)43 (91.5)90 (91.8)


Write to the Help Desk